コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tumomab pasudotox is a recombinant anti-CD22 immunotoxin.
2 e potency curve on the basis of internalized immunotoxin.
3 from humans who had been treated with ricin immunotoxin.
4 , we depleted CD4+CD25+ T cells with an IL-2 immunotoxin.
5 ncluding saline, naked hLL1, and nonspecific immunotoxin.
6 splant allografts ex vivo using an anti-CD25 immunotoxin.
7 he infected cells susceptible to an anti-HIV immunotoxin.
8 ry MLR were first depleted with an anti-CD25 immunotoxin.
9 splenectomy, rituximab (mabthera), and BL-22 immunotoxin.
10 ainst aggregation compared with the starting immunotoxin.
11 (Toxin), 3.6 micrograms rat-1, a cholinergic immunotoxin.
12 22 antibodies or our highly potent anti-CD22 immunotoxin.
13 and protein, and were sensitive to our CD22 immunotoxin.
14 monoclonal antibodies, immunoconjugates, and immunotoxins.
15 ized to improve the potency of gelonin-based immunotoxins.
16 n by antibodies, immunoconjugates, and other immunotoxins.
17 ancer therapy that employs saporin-L1-linked immunotoxins.
18 ach that may be applicable to other PE-based immunotoxins.
19 e in mediating the toxicity of anti-EGFRvIII immunotoxins.
20 t of Pseudomonas exotoxin A (PE38) to create immunotoxins.
21 at these cells cannot be killed by anti-CD22 immunotoxins.
22 gents were not cross-resistant to rGel-based immunotoxins.
23 el and promising therapeutic approaches like immunotoxins.
24 nosuppression, the animals received anti-CD3-immunotoxin (100 microg/kg(initially infused 2 hr before
28 describe high antitumor activity of a novel immunotoxin, 2L-Rap-hLL1-gamma4P, composed of 2 Rap mole
29 in vivo studies showed that an anti-RPTPbeta immunotoxin (7E4B11-SAP) could significantly delay human
30 of dorsal horn microglia with the Mac-1-SAP immunotoxin, a chemical conjugate of mouse monoclonal an
31 pies currently in clinical trials include an immunotoxin, a chimeric monoclonal antibody, and an anti
32 ts suggest that, rather than using toxins or immunotoxins, a more biological approach to decrease mus
35 yclonal or monoclonal antibodies, the use of immunotoxins, additional immunosuppressive/chemotherapeu
39 n synthesis, we show for the first time that immunotoxins also reduce the levels of selected proapopt
40 y MHC-mismatched TK transplants treated with immunotoxin and a 12-day course of CsA accepted their co
41 unologically tolerant macaques, induced with immunotoxin and deoxyspergualin, developed neither acute
42 ipients were treated with a T-cell-depleting immunotoxin and received fully MHC-mismatched TK grafts
47 nish the nonspecific toxicity of recombinant immunotoxins and other Fv fusion proteins without losing
48 22 a better therapeutic target than CD19 for immunotoxins and probably for other immunoconjugates tha
49 oning consisted of T cell depletion with CD3-immunotoxin, and 100 cGy total body irradiation prior to
50 sing number of active monoclonal antibodies, immunotoxins, and radioimmunoconjugates (RICs) has stimu
51 ll as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examin
52 roaches, including antibody-drug conjugates, immunotoxins, and targeted nucleic acid delivery, requir
53 newly developed anti-monkey CD3 recombinant immunotoxin (anti-CD3 rIT) and an anti-human CD2 antibod
56 f split PE3 offers a direct extension of the immunotoxin approach to generate bispecific agents that
69 In detail, we synthesized a novel modular immunotoxin B3(dsFv)-PE38 (B3-PE38) in which the antibod
82 an 75% of the cytotoxicity of 1,000 ng/mL of immunotoxin, but this immunogenicity was rare (5%) after
83 were treated with CsA alone or both CsA and immunotoxin, but with a normal kidney or a kidney implan
84 region of V(H) increased the potency of the immunotoxin by approximately 10-fold in a cell-killing a
86 fficacy, we have produced a less immunogenic immunotoxin by identifying and eliminating most of the B
87 pursued a strategy to deimmunize recombinant immunotoxins by identifying and removing B-cell epitopes
91 The intranasal administration of an IL-13 immunotoxin chimeric molecule (IL13-PE) from days 21-28,
92 of anti-Tac(Fv)-PE38 (LMB-2), a recombinant immunotoxin composed of a single-chain Fv fragment of th
95 LMB-2 (anti-Tac(Fv)-PE38) is a recombinant immunotoxin composed of the Fv fragment of the anti-Tac
98 cytokine, we examined whether a recombinant immunotoxin comprised of human IL-13 and a mutated form
99 ression, trafficking kinetics, extracellular immunotoxin concentration, and exposure time were all fo
102 graft model, we describe the synthesis of an immunotoxin, consisting of the F(ab')2 fragment of a mon
103 as to characterize a series of anti-Her2/neu immunotoxin constructs to identify how different antibod
106 the affinity and cytotoxicity of recombinant immunotoxins containing mouse single-chain variable regi
107 ability of an antibody to make an effective immunotoxin could not be predicted from its other functi
110 this region using HA22, an anti-CD22 Fv-PE38 immunotoxin currently undergoing clinical trials for B-c
111 We demonstrated that a CD25(high) targeting immunotoxin (denileukin diftitox) depleted FoxP3(+) Treg
114 the JAK inhibitor) quells Ab responses to an immunotoxin derived from the bacterial protein Pseudomon
117 We tested the safety and efficacy of an immunotoxin directed against a surface antigen that is s
118 ete the graft of alloreactive cells using an immunotoxin directed against the activation marker CD25.
119 l proteins and antagonizes the ability of an immunotoxin directed against the EGFRvIII to kill cells
126 that lysosomal protease digestion may limit immunotoxin efficacy unless the susceptible domain is el
128 ough specific, proteolytic cleavage with the immunotoxin EGF-SubA represents a novel and promising mu
130 n the monkey model, we examined whether this immunotoxin elicits functional responses in T cells.
132 ning of therapeutic targets, we compared two immunotoxins, FMC63(Fv)-PE38-targeting CD19 and RFB4(Fv)
134 nstrate that allodepletion with an anti-CD25 immunotoxin following stimulation with HLA-mismatched ho
138 directed mutants may increase the utility of immunotoxins for reducing or eradicating persistent HIV-
139 vity of monovalent, engineered anti-Her2/neu immunotoxins fused to recombinant gelonin (rGel) to the
144 , we eliminated these epitopes to produce an immunotoxin (HA22-LR-8M) that is fully cytotoxic against
145 pitope information, we constructed a variant immunotoxin, HA22-LR-LO10, which has low reactivity with
150 ired for many targeted therapeutics, such as immunotoxins, immunoliposomes, antibody-drug conjugates
151 ether inhibiting systemic Tregs with an IL-2 immunotoxin in a model of neu-mediated breast cancer, th
153 To trace the in vivo pharmacokinetics of the immunotoxin in mice, we labeled the antiTac(Fv)-PE38 wit
154 of T-cell-depleting antibodies, such as CD3 immunotoxin in primates and CAMPATH-1H in humans, has de
157 -infected cells are selectively killed by an immunotoxin in which a truncated form of Pseudomonas exo
158 portant clinical implications for the use of immunotoxins in the therapy of patients with cancer.
159 and the corresponding monovalent recombinant immunotoxins in two orientations, 4D5/rGel and rGel/4D5.
164 ar reservoir of CD22 decreases greatly after immunotoxin internalization, indicating that it contribu
167 particles, suggesting that this recombinant immunotoxin is a promising molecular template in drug di
170 we demonstrate that depletion using anti-CD3 immunotoxin (IT) combined with maintenance immunosuppres
172 + cells displayed relative resistance to the immunotoxin (IT) HuM195-gelonin and to free rGelonin.
173 m-cell transplants (SCTs) using an anti-CD25 immunotoxin (IT) is a strategy to prevent acute graft-ve
179 is possibility, we generated two recombinant immunotoxins (ITs) using the single-chain Fv (scFv) of M
183 or chemical intervention that could increase immunotoxin killing of cancer cells and enhance our unde
187 rm of the immune system using agents such as immunotoxins may be a useful adjuvant to existing recipi
188 Site-specific PEGylation of recombinant immunotoxins may increase their therapeutic potency in h
190 cortex infusions of a selective cholinergic immunotoxin, ME20.4-SAP, with the performance of monkeys
191 onsisting of 100 cGy total body irradiation, immunotoxin mediated T-cell depletion, and a short cours
194 expression makes it an attractive target for immunotoxin-mediated B cell depletion therapy for the tr
195 otuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-
197 ived CD3 T-lymphocyte depletion therapy with immunotoxin on the day of the transplantation (n=7) or 7
199 without rejection in 87% of recipients given immunotoxin or F(Ab)2 immunotoxin with DSG x 15 days, in
200 ul as a tumor marker, a target for cytotoxin/immunotoxin, or alternatively, a tumor-associated antige
202 were given intraventricular infusions of the immunotoxin OX7-saporin to selectively destroy Purkinje
203 cted, silencing known essential genes in the immunotoxin pathway, such as mesothelin, furin, KDEL rec
206 into 3 groups based on their effector type: immunotoxins (protein toxin), radioimmunoconjugates (rad
208 dings suggest that the newly developed ipRGC immunotoxin provides a potent method for achieving relat
210 ng cell surface receptors with cytotoxins or immunotoxins provides a unique opportunity for tumor the
211 on of the WDR85 gene could be a mechanism of immunotoxin resistance in patients undergoing immunotoxi
214 tulinum toxin type A and, more recently, the immunotoxin ricin-mAb35 have been effective as means of
222 using the axonally transported catecholamine immunotoxin, saporin-conjugated antiserum to dopamine-be
223 observation that many RNAi targets increased immunotoxin sensitivity, indicating that these gene prod
224 r refractory Hodgkin lymphoma, including the immunotoxin SGN-35 and the histone deacetylase inhibitor
225 In vivo targeting studies with an anti-CDCP1 immunotoxin showed significant inhibition of primary tum
226 mpared with unmodified LMB-2, both PEGylated immunotoxins showed similar cytotoxic activities in vitr
227 t treatment with either the mono- or dimeric immunotoxins significantly prolongs the survival of mice
228 on of human PBMC with LMB-2, a CD25-directed immunotoxin, significantly reduced CD25+ FOXP3+ CD4+ Tre
230 bsequently, mutations were made in two other immunotoxins, SS1(dsFv)-PE38 targeting ovarian cancer an
232 cantly improved the in vitro cytotoxicity of immunotoxin SS1P, which targets mesothelin and is curren
235 the framework region of the Fv portion of an immunotoxin targeting CD25 [anti-Tac(scFv)-PE38] lowered
242 responses have been observed in trials with immunotoxins targeting solid tumors, because only a sing
243 ytolethal distending toxin (Cdt) is a potent immunotoxin that induces G(2) arrest in human lymphocyte
244 binding to costimulatory molecules and of an immunotoxin that is active on T cells have been particul
246 escribe the development and validation of an immunotoxin that specifically targets the ipRGC populati
248 ategies improve the efficacy of antibody and immunotoxin therapies but have not yet been thoroughly e
252 ts over many years have produced recombinant immunotoxins; these therapeutic proteins are made using
254 on protocol combined peritransplant anti-CD3 immunotoxin to deplete T-cells and 15-deoxyspergualin to
255 similar binding of Ly-6C/Ly-6G-specific VHH immunotoxin to granulocytes and monocytes, granulocytes
258 demonstrate the capacity of a CD25-directed immunotoxin to selectively mediate a transient partial r
259 d peripheral blood mononuclear cells with an immunotoxin to stimulate T-cell expansion, followed by e
261 gated the proteolytic susceptibility of PE38 immunotoxins to lysosomal proteases and found that cleav
262 induced, splenic proliferative response from immunotoxin-treated animals further demonstrated specifi
265 clinically, we analyzed patient cells before immunotoxin treatment and report that samples of hairy c
267 ild-type or Bid knockout tumors responded to immunotoxin treatment with a decrease in growth kinetics
274 cluding monoclonal antibodies, ligand-linked immunotoxins, tyrosine kinase inhibitors, and antisense
275 hrough endosomes/lysosomes, during which the immunotoxin undergoes important proteolytic processing s
278 ion IT targeted to gp120, CD4-PE40 (chimeric immunotoxin using CD4 and the translocation and enzymati
281 gelonin (via pinocytosis) and gelonin-based immunotoxins (via antigen-dependent, receptor-mediated e
282 hypothesis directly, a new cholinergic cell immunotoxin was constructed by conjugating saporin, the
284 r leak at the same dose and, when used as an immunotoxin, was more effective in xenografted SCID mice
286 Hippocampal ChAT depletions induced by the immunotoxin were consistently greater than neocortical d
289 mmune response to the toxin component of the immunotoxin, which limits the number of cycles that can
290 cells sensitive to killing by an anti-HIV-1 immunotoxin while minimizing the side effects of CD4 and
291 with rituximab, bendamustine, and conjugate immunotoxins will reveal what role these therapies will
292 7% of recipients given immunotoxin or F(Ab)2 immunotoxin with DSG x 15 days, in 50% with DSG x 5 days
295 Injection of anti-Tac (Fv)-PE38 (LMB2), an immunotoxin with specific binding to human CD25, induced
296 asparagine 31 with arginine produced mutant immunotoxins with an affinity (0.8 nM) increased 7-fold
297 lts provide a strong rationale for combining immunotoxins with cancer vaccines for the treatment of p
298 that antibodies with increased affinity and immunotoxins with increased activity could be obtained b
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。